Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lexicon Pharmaceuticals
With
Sanofi
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants had given written informed consent to participate in the study in accordance with local regulations.
Adult participants 18 years and older with a diagnosis of T1D made at least 1 year prior to informed consent.
Participants were being treated with insulin or insulin analog delivered. via continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI).
Willing and able to perform self-monitored blood glucose (SMBG) and complete the study diary as required per protocol.
At the Screening Visit, A1C must be between 7.0% to 11.0%.
Females of childbearing potential must use an adequate method of contraception and have a negative pregnancy test .
You may not be if
Use of antidiabetic agent other than insulin or insulin analog at the time of screening.
Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to randomization.
Chronic systemic corticosteroid use.
Type 2 diabetes mellitus (T2D), or severely uncontrolled T1D as determined by the Investigator.
Clareo Health | Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
